News
-
-
-
COMMUNIQUÉ DE PRESSE
Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
Revive Therapeutics Ltd. announces strategic expansion plan for bucillamine, a potential asset for infectious diseases, nerve-agent exposure, pandemics, and medical countermeasures. Company aims to advance preclinical studies and pursue government partnerships -
-
-
COMMUNIQUÉ DE PRESSE
Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
Revive Therapeutics announces key patent milestones for Bucillamine in medical countermeasures and infectious diseases, strengthening its strategic position
